Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 11, 2026

Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 9, 2026

Stock Picks From Seeking Alpha's August 2026 New Analysts

In August, we welcomed 25 new analysts to Seeking Alpha. This article showcases their stock picks and investment strategies. Analysts provided ratings from Strong Sell to Strong Buy, with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bullish views on CTO Realty, Allogene Therapeutics, NanoXplore, Modine, and 3i Group.

Seeking Alpha • Sep 8, 2026

Allogene: If MRD Holds, This Becomes A Completely Different Company

Allogene Therapeutics presents an asymmetric setup, with the market undervaluing its focused pivot and emerging clinical validation.

Seeking Alpha • Sep 7, 2026

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.

GlobeNewsWire • Sep 2, 2026

Allogene Therapeutics Announces Participation in September Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.

GlobeNewsWire • Aug 31, 2026

Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?

Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.

Seeking Alpha • Aug 28, 2026

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Zacks Investment Research • Aug 17, 2026

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs

ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.

Zacks Investment Research • Aug 13, 2026

Allogene Therapeutics Q2 Earnings Call Highlights

Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.

MarketBeat • Aug 12, 2026